Protective effect of a new hyaluronic acid -carnosine conjugate on the modulation of the inflammatory response in mice subjected to collagen-induced arthritis

Impellizzeri, Daniela; Siracusa, Rosalba; Cordaro, Marika; Peritore, Alessio Filippo; Gugliandolo, Enrico; D’Amico, Ramona; Fusco, Roberta; Crupi, Rosalia; Rizzarelli, Enrico; Cuzzocrea, Salvatore; Vaccaro, Susanna; Pulicetta, Mariafiorenza; Greco, Valentina; Sciuto, Sebastiano; Schiavinato, Antonella; Messina, Luciano; Paola, Rosanna Di

doi:10.1016/j.biopha.2020.110023

Cited by 43 publications

(27 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was also a reduction in oxidative damage. In addition, the levels of pro-inflammatory cytokines and chemokines and COX-2 were also reduced [106].…”

Section: Osteoarthritismentioning

confidence: 97%

Hyaluronic Acid: A Key Ingredient in the Therapy of Inflammation

2021

View full text Add to dashboard Cite

Hyaluronic acid (HA) is a natural polymer, produced endogenously by the human body, which has unique physicochemical and biological properties, exhibiting desirable biocompatibility and biodegradability. Therefore, it has been widely studied for possible applications in the area of inflammatory diseases. Although exogenous HA has been described as unable to restore or replace the properties and activities of endogenous HA, it can still provide satisfactory pain relief. This review aims to discuss the advances that have been achieved in the treatment of inflammatory diseases using hyaluronic acid as a key ingredient, essentially focusing on studies carried out between the years 2017 and 2021.

show abstract

“…There was also a reduction in oxidative damage. In addition, the levels of pro-inflammatory cytokines and chemokines and COX-2 were also reduced [106].…”

Section: Osteoarthritismentioning

confidence: 97%

Hyaluronic Acid: A Key Ingredient in the Therapy of Inflammation

2021

View full text Add to dashboard Cite

show abstract

“…There is evidence, first obtained more than 25 years ago, that carnosine delays senescence, extends lifespan and even rejuvenates cultured human lung fibroblasts [5]. Subsequent studies revealed that carnosine (i) can delay ageing and/or related phenomena in some animal models [6][7][8][9][10], (ii) possesses anti-oxidant and anti-glycating activities [11][12][13][14][15], (iii) possesses anti-inflammatory properties [16][17][18][19][20], (iv) is protective towards lung injury [21][22][23], (v) can decrease the infectivity of RNA viruses Zika, Denge [24] and influenza [25], (vi) is an inhibitor of CD26 (also known and dipeptidyl peptidase IV (DPP4) [26,27] and ACE-2 (angiotensin converting enzyme 2) [28,29], i.e. the cell receptors to which COVID-19 attaches to ensure infection [30,31], (vii) can complex with zinc ions to form polaprezinc [32]; it has been reported that zinc ions can inhibit COVID-19 RNA polymerase thus suppressing viral replication [33].…”

Section: Carnosine Aging and Covid-19mentioning

confidence: 99%

COVID-19 and Senotherapeutics: Any Role for the Naturally-occurring Dipeptide Carnosine?

Hipkiss¹

2020

Aging and disease

View full text Add to dashboard Cite

It is suggested that the non-toxic dipeptide carnosine (beta-alanyl-L-histidine) should be examined as a potential protective agent against COVID-19 infection and inflammatory consequences especially in the elderly. Carnosine is an effective anti-inflammatory agent which can also inhibit CD26 and ACE2 activity. It is also suggested that nasal administration would direct the peptide directly to the lungs and escape the attention of serum carnosinase.

show abstract

“…Based on the origin, DMARDs can be classified into conventional synthetic drugs, biological drugs and biosimilars and targeted syntheticts, such as Janus kinase (Jak) inhibitors tofacitinib [4][5][6][7].The leading DMARD is methotrexate (MTX), which has been widely used to treat RA in clinic. Biological agents are used when arthritis is uncontrolled or toxic effects arise with DMARDs [8,9]. Although there are many drugs available, the therapeutic effect of the drug in many patients is still unsatisfactory.…”

Section: Introductionmentioning

confidence: 99%

Therapeutic effect of various ginsenosides on rheumatoid arthritis

Zhang

Ren

et al. 2021

BMC Complement Med Ther

View full text Add to dashboard Cite

Background Rheumatoid arthritis (RA) is an autoimmune disease which causes disability and threatens the health of humans. Therefore, it is of great significance to seek novel effective drugs for RA. It has been reported that various ginsenoside monomers are able to treat RA. However, it is still unclear which ginsenoside is the most effective and has the potential to be developed into an anti-RA drug. Methods The ginsenosides, including Rg1, Rg3, Rg5, Rb1, Rh2 and CK, were evaluated and compared for their therapeutic effect on RA. In in vitro cell studies, methotrexate (MTX) and 0.05% dimethyl sulfoxide (DMSO) was set as a positive control group and a negative control group, respectively. LPS-induced RAW264.7 cells and TNF-α-induced HUVEC cells were cultured with MTX, DMSO and six ginsenosides, respectively. Cell proliferation was analyzed by MTT assay and cell apoptosis was carried out by flow cytometry. CIA mice model was developed to evaluate the therapeutic efficacy of ginsenosides. The analysis of histology, immunohistochemistry, flow cytometry and cytokine detections of the joint tissues were performed to elucidate the action mechanisms of ginsenosides. Results All six ginsenosides showed good therapeutic effect on acute arthritis compared with the negative control group, Ginsenoside CK provided the most effective treatment ability. It could significantly inhibit the proliferation and promote the apoptosis of RAW 264.7 and HUVEC cells, and substantially reduce the swelling, redness, functional impairment of joints and the pathological changes of CIA mice. Meanwhile, CK could increase CD8 + T cell to down-regulate the immune response, decrease the number of activated CD4 + T cell and proinflammatory M1-macrophages, thus resulting in the inhibition of the secretion of proinflammatory cytokine such as TNF-α and IL-6. Conclusion Ginsenoside CK was proved to be a most potential candidate among the tested ginsenosides for the treatment of RA, with a strong anti-inflammation and immune modulating capabilities.

show abstract

Protective effect of a new hyaluronic acid -carnosine conjugate on the modulation of the inflammatory response in mice subjected to collagen-induced arthritis

Cited by 43 publications

References 56 publications

Hyaluronic Acid: A Key Ingredient in the Therapy of Inflammation

Hyaluronic Acid: A Key Ingredient in the Therapy of Inflammation

COVID-19 and Senotherapeutics: Any Role for the Naturally-occurring Dipeptide Carnosine?

Therapeutic effect of various ginsenosides on rheumatoid arthritis

Contact Info

Product

Resources

About